MediWound Ltd. (NASDAQ:MDWD – Get Rating) – Research analysts at Oppenheimer raised their Q4 2022 earnings per share estimates for MediWound in a research report issued to clients and investors on Tuesday, January 17th. Oppenheimer analyst F. Brisebois now expects that the biopharmaceutical company will earn $0.53 per share for the quarter, up from their prior forecast of ($0.40). The consensus estimate for MediWound’s current full-year earnings is ($2.71) per share. Oppenheimer also issued estimates for MediWound’s Q1 2023 earnings at ($0.60) EPS, Q2 2023 earnings at ($0.54) EPS, Q3 2023 earnings at ($0.55) EPS, Q4 2023 earnings at ($0.56) EPS and FY2023 earnings at ($2.26) EPS.
MediWound (NASDAQ:MDWD – Get Rating) last issued its earnings results on Tuesday, November 15th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.21). The firm had revenue of $5.80 million during the quarter, compared to the consensus estimate of $4.65 million.
MediWound Stock Down 0.6 %
Shares of NASDAQ:MDWD opened at $13.58 on Friday. MediWound has a twelve month low of $8.05 and a twelve month high of $18.76. The stock’s 50 day moving average is $12.72 and its 200-day moving average is $12.03. The firm has a market capitalization of $79.05 million, a price-to-earnings ratio of -3.66 and a beta of 0.99.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC bought a new position in MediWound in the 3rd quarter valued at $405,000. Sargent Investment Group LLC grew its stake in MediWound by 7.2% in the 3rd quarter. Sargent Investment Group LLC now owns 562,350 shares of the biopharmaceutical company’s stock valued at $799,000 after purchasing an additional 37,600 shares during the period. Renaissance Technologies LLC grew its stake in MediWound by 3.8% in the 2nd quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock valued at $875,000 after purchasing an additional 17,600 shares during the period. Altium Capital Management LP bought a new position in MediWound in the 3rd quarter valued at $1,775,000. Finally, Armistice Capital LLC bought a new position in MediWound in the 3rd quarter valued at $2,663,000. Institutional investors own 13.58% of the company’s stock.
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
- Get a free copy of the StockNews.com research report on MediWound (MDWD)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.